SuperworthInsulet profit margin PODD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 12.3%
- Operating margin, 12 months
- 16.9%
- Net margin on a year earlier
- +2.3 pts
- Peer median
- 12.4%
Over the twelve months to Jun 30, 2026, Insulet kept 12.3% of its revenue as net profit, with an operating margin of 16.9% and a gross margin of 71.1%.
Five years earlier its net margin was −3.1%.
The median for 10 medical instruments and supplies stocks of a similar size is 12.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 9.1% | 17.5% | 71.6% |
| FY2024 | 20.2% | 14.9% | 69.8% |
| FY2023 | 12.2% | 13.0% | 68.3% |
| FY2022 | 0.4% | 2.9% | 61.7% |
| FY2021 | 1.5% | 11.5% | 68.4% |
| FY2020 | 0.8% | 5.7% | 64.4% |
| FY2019 | 1.6% | 6.8% | 65.1% |
| FY2018 | 0.6% | 4.9% | 65.7% |
| FY2017 | −5.8% | −1.6% | 59.8% |
| FY2016 | −7.9% | −2.9% | 57.5% |
| FY2015 | −27.9% | −18.5% | 50.5% |
| FY2014 | −17.8% | −4.3% | 49.6% |
| FY2013 | −18.2% | −11.8% | 45.5% |
| FY2012 | −24.5% | −17.0% | 43.7% |
| FY2011 | −30.1% | −27.9% | 43.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 12.3% | +2.3 pts | 16.9% | |
| Q1 FY26 | 10.4% | −7.9 pts | 17.5% | |
| Q4 FY25 | 9.1% | −11.1 pts | 17.5% | |
| Q3 FY25 | 9.8% | −11.5 pts | 17.3% | |
| Q2 FY25 | 10.0% | −11.1 pts | 17.3% | |
| Q1 FY25 | 18.3% | +5.2 pts | 15.5% | |
| Q4 FY24 | 20.2% | +8.0 pts | 14.9% | |
| Q3 FY24 | 21.2% | +13.5 pts | 15.4% | |
| Q2 FY24 | 21.1% | +16.8 pts | 14.6% | |
| Q1 FY24 | 13.1% | +13.1 pts | 14.0% | |
| Q4 FY23 | 12.2% | +11.8 pts | 13.0% | |
| Q3 FY23 | 7.7% | +6.4 pts | 8.8% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Insulet's size, closest first, today.
| Company | Profit margin |
|---|---|
| PODDInsulet | 12.3% |
| GMEDGlobus Medical | 17.0% |
| ALGNAlign Technology | 10.0% |
| COOCooper Companies | 13.5% |
| PENPenumbra | 10.7% |
| SOLVSolventum | 17.3% |
| MSAMSA Safety | 16.1% |
| MMSIMerit Medical Systems | 9.2% |
| HAEHaemonetics | 7.1% |
| VNTVontier | 11.3% |
| BMIBadger Meter | 14.3% |
| Peer median | 12.4% |
Where Insulet ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Insulet
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.